Our UHN programs and services are among the most advanced in the world. We have grouped our physicians, staff, services and resources into 10 medical programs to meet the needs of our patients and help us make the most of our resources.
University Health Network is a health care and medical research organization in Toronto, Ontario, Canada. The scope of research and complexity of cases at UHN has made us a national and international source for discovery, education and patient care.
Our 10 medical programs are spread across eight hospital sites – Princess Margaret, Toronto General, Toronto Rehab’s five sites, Toronto Western – as well as our education programs through the Michener Institute of Education at UHN. Learn more about the services, programs and amenities offered at each location.
Maps & Directions
Find out how to get to and around our nine locations — floor plans, parking, public transit, accessibility services, and shuttle information.
Ways You Can Help
Being touched by illness affects us in different ways. Many people want to give back to the community and help others. At UHN, we welcome your contribution and offer different ways you can help so you can find one that suits you.
The Newsroom is the source for media looking for information about UHN or trying to connect with one of our experts for an interview. It’s also the place to find UHN media policies and catch up on our news stories, videos, media releases, podcasts and more.
A research team led by Dr. Tony Lam, John Kitson McIvor Chair in Diabetes Research at the Toronto General Research Institute, TGH, has discovered a novel function of a hormone found in the gut that could lower glucose levels in diabetes. The research paper, "Intestinal Cholecystokinin controls Glucose Production through a Neuronal Network," appeared in the August issue of the journal Cell Metabolism. The research was funded by the Canadian Institutes of Health Research.Dr. Lam's team has found that activating receptors of the cholecystokinin (CCK) peptide hormone in the gut rapidly and potently lowers blood glucose levels by triggering a signal, first to the brain and then to the liver, to lower glucose or sugar production. "Our findings reveal a novel role for the CCK hormone and suggest that CCK-resistance in the gut may contribute to high blood sugar levels… Understanding how to overcome CCK-resistance in the gut so that blood sugars can be lowered could be a novel therapeutic approach to diabetes and obesity," says Dr. Lam. "This paper compliments our study that was published last year in Nature indicating that in the future, we may be able to design a drug to target the gut to lower glucose levels in patients with diabetes."However, the clinical therapeutic implications of the current findings are still largely unknown, and much more time will be needed to determine whether enhancing CCK action in the gut of humans is effective and safe in lowering glucose levels in healthy individuals as well as patients with diabetes and obesity.